Share Price and Basic Stock Data
Last Updated: January 16, 2026, 8:24 pm
| PEG Ratio | -15.69 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Arvee Laboratories (India) Ltd operates in the specialty chemicals sector, with a market capitalization of ₹208 Cr and a current share price of ₹189. The company has experienced fluctuating revenue trends, with sales reported at ₹61.35 Cr for the fiscal year ending March 2023, a significant increase from ₹40.33 Cr in FY 2022. However, the trailing twelve months (TTM) revenue stands at ₹26.29 Cr, indicating a decline in sales momentum. Quarterly sales figures reveal a downward trajectory, with ₹12.56 Cr in March 2023 declining to ₹7.60 Cr in June 2023, followed by a slight recovery to ₹8.91 Cr in September 2023. This inconsistency raises concerns over the company’s ability to sustain revenue growth, particularly as sales for FY 2024 are reported at ₹30.35 Cr, which is a decrease compared to the previous fiscal year. Such trends warrant scrutiny as they may reflect underlying operational challenges or market dynamics affecting demand for specialty chemicals.
Profitability and Efficiency Metrics
Arvee Laboratories reported an operating profit margin (OPM) of 3.48% as of the latest quarter, indicating challenges in maintaining profitability. The company’s net profit for FY 2025 stood at ₹2.15 Cr, down from ₹4.12 Cr in FY 2023, which translates to a net profit margin of 5.57%. This decline in profitability is concerning, particularly given the high P/E ratio of 520, which suggests that the stock may be overvalued relative to its earnings. Efficiency metrics show a cash conversion cycle (CCC) of 102.25 days, which is significantly longer than typical industry standards, indicating inefficiencies in managing working capital. The return on equity (ROE) is reported at 7.12%, while return on capital employed (ROCE) stands at 10.0%. These figures are below average for the sector, suggesting that the company may not be utilizing its resources effectively to generate returns.
Balance Sheet Strength and Financial Ratios
The balance sheet of Arvee Laboratories reflects a conservative capital structure, with total borrowings reported at ₹1.03 Cr, contributing to a total debt-to-equity ratio of 0.03. This low leverage indicates a lower risk profile, but it also raises questions about the company’s growth potential through debt financing. Reserves have increased to ₹20.42 Cr, providing a cushion for future investments or operational needs. The current ratio is a robust 5.14, suggesting strong liquidity, while the quick ratio stands at 3.95, indicating that the company can readily meet its short-term obligations. However, the interest coverage ratio (ICR) at 17.19x demonstrates that the company can comfortably cover its interest expenses, reflecting sound financial health. Overall, while the balance sheet shows strength in liquidity and low leverage, the lack of aggressive growth strategies could hinder future expansion.
Shareholding Pattern and Investor Confidence
Arvee Laboratories has a stable shareholding pattern, with promoters holding a significant 73.50% stake, indicating strong control and commitment to the company’s vision. The public holds the remaining 26.50%, with a total of 1,505 shareholders as of the latest reporting period. This concentration of ownership can be both a strength and a risk; while it provides stability, it may also limit liquidity and investor interest from institutional players, as foreign institutional investors (FIIs) and domestic institutional investors (DIIs) are not reported. The increase in the number of shareholders from 866 in December 2022 to 1,505 suggests growing interest among retail investors, which could enhance market confidence. However, the lack of institutional backing may pose challenges in raising capital for future growth initiatives.
Outlook, Risks, and Final Insight
The outlook for Arvee Laboratories appears mixed, with strengths in liquidity and a strong promoter stake providing a foundation for potential recovery. However, the declining revenue trends and profitability metrics are significant risks that could hinder growth. The company’s high P/E ratio indicates that investors may have high expectations for future performance, which could lead to volatility if these expectations are not met. Operational inefficiencies, as reflected in the extended cash conversion cycle, also pose challenges. Moving forward, the company could explore strategic partnerships or investments in operational efficiencies to enhance profitability. An aggressive marketing strategy to boost sales in the specialty chemicals market may also be beneficial. If Arvee Laboratories can address these challenges effectively, it may regain investor confidence and stabilize its financial performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 362 Cr. | 39.4 | 75.0/39.0 | 22.5 | 20.5 | 1.01 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 29.0 Cr. | 59.0 | 88.8/55.0 | 13.9 | 89.6 | 1.69 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.9 Cr. | 689 | 907/600 | 21.6 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,317 Cr. | 73.2 | 111/68.2 | 22.0 | 22.0 | 0.68 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 566 Cr. | 227 | 393/225 | 20.3 | 93.8 | 1.08 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,588.88 Cr | 681.55 | 63.06 | 182.97 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.74 | 16.25 | 12.56 | 7.60 | 8.91 | 7.70 | 6.14 | 10.60 | 12.53 | 8.91 | 6.45 | 7.48 | 3.45 |
| Expenses | 19.48 | 14.51 | 11.40 | 6.62 | 8.22 | 7.17 | 5.35 | 9.06 | 11.03 | 8.57 | 6.23 | 7.14 | 3.33 |
| Operating Profit | 3.26 | 1.74 | 1.16 | 0.98 | 0.69 | 0.53 | 0.79 | 1.54 | 1.50 | 0.34 | 0.22 | 0.34 | 0.12 |
| OPM % | 14.34% | 10.71% | 9.24% | 12.89% | 7.74% | 6.88% | 12.87% | 14.53% | 11.97% | 3.82% | 3.41% | 4.55% | 3.48% |
| Other Income | 0.06 | 0.07 | 0.06 | 0.09 | 0.09 | 0.19 | 0.21 | 0.11 | 0.16 | 0.19 | 0.21 | 0.17 | 0.23 |
| Interest | 0.11 | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | 0.05 | 0.08 | 0.05 | 0.05 | 0.07 | 0.04 | 0.04 |
| Depreciation | 0.48 | 0.49 | 0.48 | 0.35 | 0.42 | 0.35 | 0.37 | 0.31 | 0.30 | 0.28 | 0.27 | 0.29 | 0.30 |
| Profit before tax | 2.73 | 1.23 | 0.67 | 0.65 | 0.28 | 0.32 | 0.58 | 1.26 | 1.31 | 0.20 | 0.09 | 0.18 | 0.01 |
| Tax % | 25.27% | 25.20% | 100.00% | 24.62% | 25.00% | 25.00% | 81.03% | 25.40% | 25.19% | 25.00% | 22.22% | 5.56% | 0.00% |
| Net Profit | 2.05 | 0.92 | 0.01 | 0.49 | 0.21 | 0.24 | 0.12 | 0.94 | 0.98 | 0.15 | 0.07 | 0.17 | 0.01 |
| EPS in Rs | 1.86 | 0.83 | 0.01 | 0.44 | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 | 0.01 |
Last Updated: January 2, 2026, 11:00 am
Below is a detailed analysis of the quarterly data for Arvee Laboratories (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 3.45 Cr.. The value appears to be declining and may need further review. It has decreased from 7.48 Cr. (Jun 2025) to 3.45 Cr., marking a decrease of 4.03 Cr..
- For Expenses, as of Sep 2025, the value is 3.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.14 Cr. (Jun 2025) to 3.33 Cr., marking a decrease of 3.81 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 0.34 Cr. (Jun 2025) to 0.12 Cr., marking a decrease of 0.22 Cr..
- For OPM %, as of Sep 2025, the value is 3.48%. The value appears to be declining and may need further review. It has decreased from 4.55% (Jun 2025) to 3.48%, marking a decrease of 1.07%.
- For Other Income, as of Sep 2025, the value is 0.23 Cr.. The value appears strong and on an upward trend. It has increased from 0.17 Cr. (Jun 2025) to 0.23 Cr., marking an increase of 0.06 Cr..
- For Interest, as of Sep 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.04 Cr..
- For Depreciation, as of Sep 2025, the value is 0.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.29 Cr. (Jun 2025) to 0.30 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.18 Cr. (Jun 2025) to 0.01 Cr., marking a decrease of 0.17 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 5.56% (Jun 2025) to 0.00%, marking a decrease of 5.56%.
- For Net Profit, as of Sep 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.17 Cr. (Jun 2025) to 0.01 Cr., marking a decrease of 0.16 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.15 (Jun 2025) to 0.01, marking a decrease of 0.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:38 am
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | 38.49 | 26.29 |
| Expenses | 21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.41 | 34.88 | 25.27 |
| Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 2.94 | 3.61 | 1.02 |
| OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.69% | 9.38% | 3.88% |
| Other Income | 0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.64 | 0.66 | 0.80 |
| Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 | 0.25 | 0.20 |
| Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 | 1.15 | 1.14 |
| Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 | 2.87 | 0.48 |
| Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% | 25.09% | |
| Net Profit | 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | 2.15 | 0.40 |
| EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 | 1.95 | 0.36 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 715.79% | -29.68% | 107.34% | 1.77% | 16.52% | -4.10% | 60.31% | -74.51% | 104.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -745.47% | 137.02% | -105.57% | 14.75% | -20.63% | 64.42% | -134.83% | 179.28% |
Arvee Laboratories (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 22% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 7% |
Last Updated: September 4, 2025, 11:40 pm
Balance Sheet
Last Updated: December 10, 2025, 2:23 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 | 20.24 | 20.42 |
| Borrowings | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.03 | 1.03 |
| Other Liabilities | 7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.08 | 5.87 | 8.11 |
| Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
| Fixed Assets | 13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.67 | 15.27 | 15.25 |
| CWIP | 4.30 | 0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 | 0.73 | 0.81 |
| Investments | 0.00 | 0.00 | 0.00 | 1.95 | 3.09 | 2.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 22.90 | 22.16 | 24.52 |
| Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 38.16 | 40.58 |
Below is a detailed analysis of the balance sheet data for Arvee Laboratories (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.02 Cr..
- For Reserves, as of Sep 2025, the value is 20.42 Cr.. The value appears strong and on an upward trend. It has increased from 20.24 Cr. (Mar 2025) to 20.42 Cr., marking an increase of 0.18 Cr..
- For Borrowings, as of Sep 2025, the value is 1.03 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 1.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.87 Cr. (Mar 2025) to 8.11 Cr., marking an increase of 2.24 Cr..
- For Total Liabilities, as of Sep 2025, the value is 40.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.16 Cr. (Mar 2025) to 40.58 Cr., marking an increase of 2.42 Cr..
- For Fixed Assets, as of Sep 2025, the value is 15.25 Cr.. The value appears to be declining and may need further review. It has decreased from 15.27 Cr. (Mar 2025) to 15.25 Cr., marking a decrease of 0.02 Cr..
- For CWIP, as of Sep 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.73 Cr. (Mar 2025) to 0.81 Cr., marking an increase of 0.08 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 24.52 Cr.. The value appears strong and on an upward trend. It has increased from 22.16 Cr. (Mar 2025) to 24.52 Cr., marking an increase of 2.36 Cr..
- For Total Assets, as of Sep 2025, the value is 40.58 Cr.. The value appears strong and on an upward trend. It has increased from 38.16 Cr. (Mar 2025) to 40.58 Cr., marking an increase of 2.42 Cr..
Notably, the Reserves (20.42 Cr.) exceed the Borrowings (1.03 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.33 | -19.09 | -8.98 | -6.70 | 2.15 | -2.81 | 2.55 | 6.29 | 1.94 | 2.58 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 | 79.66 |
| Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 159.02 | 80.31 |
| Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 164.49 | 57.72 |
| Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 | 102.25 |
| Working Capital Days | 30.08 | 30.84 | 30.79 | -6.52 | 10.29 | -10.63 | 49.96 | 70.44 | 95.97 | 106.59 |
| ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% | 10.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Diluted EPS (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| Cash EPS (Rs.) | 2.99 | 2.31 | 5.63 | 4.44 | 4.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.37 | 26.42 | 25.46 | 21.73 | 19.45 |
| Revenue From Operations / Share (Rs.) | 34.92 | 27.54 | 55.67 | 36.59 | 42.99 |
| PBDIT / Share (Rs.) | 3.87 | 3.25 | 7.83 | 5.56 | 6.01 |
| PBIT / Share (Rs.) | 2.83 | 1.89 | 5.95 | 3.46 | 3.83 |
| PBT / Share (Rs.) | 2.61 | 1.66 | 5.59 | 3.13 | 3.30 |
| Net Profit / Share (Rs.) | 1.95 | 0.95 | 3.74 | 2.34 | 2.43 |
| PBDIT Margin (%) | 11.08 | 11.78 | 14.07 | 15.19 | 13.98 |
| PBIT Margin (%) | 8.10 | 6.85 | 10.68 | 9.44 | 8.90 |
| PBT Margin (%) | 7.45 | 6.02 | 10.04 | 8.55 | 7.68 |
| Net Profit Margin (%) | 5.57 | 3.46 | 6.71 | 6.38 | 5.65 |
| Return on Networth / Equity (%) | 6.86 | 3.61 | 14.67 | 10.75 | 12.48 |
| Return on Capital Employeed (%) | 9.24 | 6.65 | 21.95 | 15.14 | 18.53 |
| Return On Assets (%) | 5.71 | 2.75 | 10.64 | 6.65 | 6.52 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.03 | 0.03 | 0.03 | 0.13 | 0.41 |
| Asset Turnover Ratio (%) | 1.02 | 0.78 | 1.59 | 1.01 | 1.27 |
| Current Ratio (X) | 5.14 | 2.42 | 2.44 | 1.75 | 1.40 |
| Quick Ratio (X) | 3.95 | 1.50 | 1.92 | 1.33 | 0.99 |
| Inventory Turnover Ratio (X) | 7.03 | 3.08 | 7.48 | 3.53 | 4.18 |
| Interest Coverage Ratio (X) | 17.19 | 14.34 | 22.25 | 17.08 | 11.49 |
| Interest Coverage Ratio (Post Tax) (X) | 9.65 | 5.22 | 11.62 | 8.17 | 5.64 |
| Enterprise Value (Cr.) | 152.60 | 157.16 | 97.08 | 123.80 | 63.32 |
| EV / Net Operating Revenue (X) | 3.96 | 5.18 | 1.58 | 3.07 | 1.34 |
| EV / EBITDA (X) | 35.75 | 43.93 | 11.25 | 20.20 | 9.56 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| Price / BV (X) | 5.01 | 5.43 | 3.46 | 5.23 | 2.85 |
| Price / Net Operating Revenue (X) | 4.07 | 5.21 | 1.58 | 3.11 | 1.29 |
| EarningsYield | 0.01 | 0.01 | 0.04 | 0.02 | 0.04 |
After reviewing the key financial ratios for Arvee Laboratories (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 5. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 2.31 (Mar 24) to 2.99, marking an increase of 0.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.37. It has increased from 26.42 (Mar 24) to 28.37, marking an increase of 1.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 34.92. It has increased from 27.54 (Mar 24) to 34.92, marking an increase of 7.38.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.87. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 3.87, marking an increase of 0.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.83, marking an increase of 0.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 2.61, marking an increase of 0.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.95. This value is below the healthy minimum of 2. It has increased from 0.95 (Mar 24) to 1.95, marking an increase of 1.00.
- For PBDIT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 11.08, marking a decrease of 0.70.
- For PBIT Margin (%), as of Mar 25, the value is 8.10. This value is below the healthy minimum of 10. It has increased from 6.85 (Mar 24) to 8.10, marking an increase of 1.25.
- For PBT Margin (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 10. It has increased from 6.02 (Mar 24) to 7.45, marking an increase of 1.43.
- For Net Profit Margin (%), as of Mar 25, the value is 5.57. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 5.57, marking an increase of 2.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 15. It has increased from 3.61 (Mar 24) to 6.86, marking an increase of 3.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.24. This value is below the healthy minimum of 10. It has increased from 6.65 (Mar 24) to 9.24, marking an increase of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 5.71. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 5.71, marking an increase of 2.96.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. It has increased from 0.78 (Mar 24) to 1.02, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 5.14. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 5.14, marking an increase of 2.72.
- For Quick Ratio (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.95, marking an increase of 2.45.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.03. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 7.03, marking an increase of 3.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.19. This value is within the healthy range. It has increased from 14.34 (Mar 24) to 17.19, marking an increase of 2.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.65. This value is within the healthy range. It has increased from 5.22 (Mar 24) to 9.65, marking an increase of 4.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 152.60. It has decreased from 157.16 (Mar 24) to 152.60, marking a decrease of 4.56.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.96. This value exceeds the healthy maximum of 3. It has decreased from 5.18 (Mar 24) to 3.96, marking a decrease of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 35.75. This value exceeds the healthy maximum of 15. It has decreased from 43.93 (Mar 24) to 35.75, marking a decrease of 8.18.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For Price / BV (X), as of Mar 25, the value is 5.01. This value exceeds the healthy maximum of 3. It has decreased from 5.43 (Mar 24) to 5.01, marking a decrease of 0.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has decreased from 5.21 (Mar 24) to 4.07, marking a decrease of 1.14.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arvee Laboratories (India) Ltd:
- Net Profit Margin: 5.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.24% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.86% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 489 (Industry average Stock P/E: 63.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 403, Entice, Nr. Jayantilal Park BRTS, Ahmedabad Gujarat 380058 | compliance@arveelabs.com http://www.arveelabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shalin Sudhakarbhai Patel | Managing Director |
| Mr. Shalin Bharat Chokshi | Whole Time Director |
| Mrs. Neetu Rishi Jalan | Ind.& Non Exe.Director |
| Mr. Sachin Kanwarlal Kansal | Ind.& Non Exe.Director |
| Ms. Shalini Hitesh Jalan | Ind.& Non Exe.Director |
FAQ
What is the intrinsic value of Arvee Laboratories (India) Ltd?
Arvee Laboratories (India) Ltd's intrinsic value (as of 16 January 2026) is ₹809.70 which is 354.89% higher the current market price of ₹178.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹196 Cr. market cap, FY2025-2026 high/low of ₹291/127, reserves of ₹20.42 Cr, and liabilities of ₹40.58 Cr.
What is the Market Cap of Arvee Laboratories (India) Ltd?
The Market Cap of Arvee Laboratories (India) Ltd is 196 Cr..
What is the current Stock Price of Arvee Laboratories (India) Ltd as on 16 January 2026?
The current stock price of Arvee Laboratories (India) Ltd as on 16 January 2026 is ₹178.
What is the High / Low of Arvee Laboratories (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Arvee Laboratories (India) Ltd stocks is ₹291/127.
What is the Stock P/E of Arvee Laboratories (India) Ltd?
The Stock P/E of Arvee Laboratories (India) Ltd is 489.
What is the Book Value of Arvee Laboratories (India) Ltd?
The Book Value of Arvee Laboratories (India) Ltd is 28.5.
What is the Dividend Yield of Arvee Laboratories (India) Ltd?
The Dividend Yield of Arvee Laboratories (India) Ltd is 0.00 %.
What is the ROCE of Arvee Laboratories (India) Ltd?
The ROCE of Arvee Laboratories (India) Ltd is 10.0 %.
What is the ROE of Arvee Laboratories (India) Ltd?
The ROE of Arvee Laboratories (India) Ltd is 7.12 %.
What is the Face Value of Arvee Laboratories (India) Ltd?
The Face Value of Arvee Laboratories (India) Ltd is 10.0.